Prime Medicine Inc. logo

Prime Medicine Inc. (PRME)

Market Closed
25 Jul, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
4. 21
-0.14
-3.22%
$
609.27M Market Cap
- P/E Ratio
0% Div Yield
2,134,887 Volume
-1.83 Eps
$ 4.35
Previous Close
Day Range
4.17 4.37
Year Range
1.11 5.95
Want to track PRME and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 12 days

Summary

PRME closed today lower at $4.21, a decrease of 3.22% from yesterday's close, completing a monthly decrease of -8.48% or $0.39. Over the past 12 months, PRME stock gained 43.69%.
PRME is not paying dividends to its shareholders.
The last earnings report, released on May 09, 2025, missed the consensus estimates by -0.09%. On average, the company has fell short of earnings expectations by -0.04%, based on the last three reports. The next scheduled earnings report is due on Aug 06, 2025.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).

PRME Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
Prime Medicine: Pressing Forward With Lead Liver Targeting Indications

Prime Medicine: Pressing Forward With Lead Liver Targeting Indications

Prime Medicine, Inc. achieved strong early data in CGD with PM359, surpassing efficacy thresholds, but is pivoting to larger in-vivo gene editing liver disease targeting opportunities. PRME is prioritizing in-vivo gene editing therapy programs targeting Wilson's Disease and Alpha-1 Antitrypsin Deficiency, with IND filings expected in H1 and mid-2026, respectively. These new programs use in-vivo LNP delivery, target larger markets, and could provide substantially better advantages for PRME over ex-vivo gene editing.

Seekingalpha | 2 weeks ago
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates

Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates

Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.44 per share a year ago.

Zacks | 2 months ago
Why Prime Medicine Stock Was Climbing Higher This Week

Why Prime Medicine Stock Was Climbing Higher This Week

News of a fresh investigational program was putting some zip into the shares of gene-editing company Prime Medicine (PRME) across recent trading sessions. According to data compiled by S&P Global Market Intelligence, in reaction, bullish investors were propelling the company's stock over 12% higher week to date as of early Thursday evening.

Fool | 4 months ago

Prime Medicine Inc. Dividends

PRME is not paying dividends to its shareholders.

Prime Medicine Inc. Earnings

14 Aug 2025 (In 2 weeks) Date
-
Cons. EPS
-
EPS
6 Aug 2025 (In 1 week) Date
-
Cons. EPS
-
EPS
9 May 2025 Date
-
Cons. EPS
-
EPS
28 Feb 2025 Date
-
Cons. EPS
-
EPS
13 Nov 2024 Date
-
Cons. EPS
-
EPS
PRME is not paying dividends to its shareholders.
14 Aug 2025 (In 2 weeks) Date
-
Cons. EPS
-
EPS
6 Aug 2025 (In 1 week) Date
-
Cons. EPS
-
EPS
9 May 2025 Date
-
Cons. EPS
-
EPS
28 Feb 2025 Date
-
Cons. EPS
-
EPS
13 Nov 2024 Date
-
Cons. EPS
-
EPS

Prime Medicine Inc. (PRME) FAQ

What is the stock price today?

The current price is $4.21.

On which exchange is it traded?

Prime Medicine Inc. is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is PRME.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 609.27M.

When is the next earnings date?

The next earnings report will release on Aug 06, 2025.

Has Prime Medicine Inc. ever had a stock split?

No, there has never been a stock split.

Prime Medicine Inc. Profile

Biotechnology Industry
Healthcare Sector
Jeremy S. Duffield CEO
NASDAQ (NMS) Exchange
74168J101 Cusip
US Country
214 Employees
- Last Dividend
- Last Split
20 Oct 2022 IPO Date

Overview

Prime Medicine, Inc. is a biotechnology enterprise specialized in pioneering genetic therapies to combat a broad spectrum of diseases by harnessing the power of gene editing technology. Established in 2019, the company positions itself at the forefront of genetic medicine with its innovative approach to editing DNA sequences. Operating from its headquarters in Cambridge, Massachusetts, Prime Medicine is dedicated to realizing the potential of genetic correction and modification to treat conditions that have long been considered untreatable. The company has embarked on a significant collaboration with Cimeio Therapeutics, focusing on the development of Prime Edited Shielded-Cell & Immunotherapy Pairs, targeting genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome.

Products and Services

  • Prime Editors
  • At the core of Prime Medicine's offerings are the Prime Editors, a revolutionary gene editing tool. This technology combines a Prime Editor protein, which is a fusion of a Cas protein and a reverse transcriptase enzyme, with a pegRNA (prime editing guide RNA). The pegRNA is crucial as it not only directs the Prime Editor to a specific location within the genome but also supplies the template needed for executing the desired edit on the target DNA sequence. This sophisticated mechanism allows for precision in gene editing, paving the way for treatment strategies that could correct genetic mutations at their source.

  • Collaborative Research Projects
  • Underpinning Prime Medicine's innovative technology is its strategic research collaboration with Cimeio Therapeutics. This partnership is primarily focused on the development of Prime Edited Shielded-Cell & Immunotherapy Pairs. These novel therapeutic strategies are designed to treat a range of conditions, from genetic diseases to cancers like acute myeloid leukemia and myelodysplastic syndrome. This collaboration highlights Prime Medicine's commitment to leveraging its technology in concert with other biotech entities to address complex medical challenges.

Contact Information

Address: 21 Erie Street
Phone: 617-564-0013